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ABSTRACT
The purpose of this study was to investigate whether splenectomy influences the 
tumor growth and metastatic pattern in an orthotopic syngeneic murine pancreatic 
cancer model. Murine pancreatic cancer cells (PAN02) were subcutaneously injected 
into the flanks of nude mice. A small tumor fragment (3 mm2), harvested from a 
subcutaneous tumor. was orthotopically implanted in the tail of the pancreas of 
C57/BL6 mice without splenectomy (control group, n=15) or with simultaneous 
splenectomy (splenectomy group, n=15). Tumor growth and metastatic patterns were 
analyzed by laparotomy at 21 days after surgery. No tumor growth was found in 5 
mice (33.3%) of the control group and 1 mouse (6.7%) of the splenectomy group 
(p=0.169). Tumor volume was significantly larger in splenectomy group (p=0.013). 
Peritoneal seeding was more frequently observed in the splenectomy group (11 
(73.3%) vs. 4 (26.7%), p=0.011). There were no differences in the number of liver 
and kidney metastasis between the two groups. The ratios of tumor-infiltrating CD4+ 
to FoxP3+ and CD8+ to FoxP3+ were significantly higher in the control group compared 
to the splenectomy group (8.2 ± 9.3 vs. 2.4 ± 1.5, p=0.046; 2.5 ± 1.4 vs. 1.5 ± 0.4, 
p=0.031, respectively). Splenectomy enhanced tumor growth and peritoneal seeding 
in an orthotopic syngeneic murine pancreatic cancer mouse model. The ramification 
of these results are discussed for pancreatic cancer treatment.
INTRODUCTION
Distal pancreatectomy including splenectomy has been 
accepted as the standard procedure for left-sided pancreatic 
ductal adenocarcinoma (PDAC) [1, 2]. Splenectomy can 
clear regional lymph nodes of pancreatic cancer cells. If the 
tumor is located away from the splenic hilum and there is no 
evidence of nodal metastasis around the spleen, splenectomy 
may not be necessary for distal pancreatectomy. We 
previously reported in an international multi-center survey, 
that in such cases, splenectomy-omitting radical distal 
pancreatectomy would be feasible [3].
Splenectomy has been shown to have a negative effect 
on cancer survival of patients with gastric and colon cancer 
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[4–6]. Schwarz et al reported that splenectomy had a negative 
influence on long-term survival after pancreatectomy for 
PDAC [7]. The number of hepatic and lung metastases 
increased in splenectomized mice using colon cancer and 
liver tumor models [8–10]. In terms of PDAC, there is no 
mouse model study to demonstrate the role of the spleen for 
tumor growth and metastasis or oncologic outcome.
The purpose of this study was to investigate whether 
splenectomy influences the tumor growth pattern, as well 
as host immunity, in an orthotopic syngeneic murine 
pancreatic cancer model.
RESULTS
Tumor growth patterns
The mice were divided into two groups according 
to splenectomy or no splenectomy (Figure 1). After the 
spleen was removed, a single tumor fragment was sutured 
to the pancreatic tail by surgical orthotopic implantation 
(SOI) (Figure 2). Fifteen mice were used in both the 
control and splenectomy groups. Body weight at SOI and 
laparotomy was not different between the splenectomy 
and non-splenectomy groups. In the splenectomy group, 
one mouse was died at 19 days after surgery. The mouse 
had severe ascites and multiple peritoneal seeding at 
laparotomy. In one mouse in the control group, the 
implanted tumor could not be identified at the pancreatic 
tail and only suture material was observed. Peritoneal 
fat was attached around the surgical bed. We defined 
this mouse as ‘tumor rejection’. If the implanted tumor 
grew to less than 5 mm, the mouse was defined as ‘no 
growth’. No tumor growth was observed in 5 mice 
(33.3%) of the control group and 1 mouse (6.7%) of the 
splenectomy group. There was no statistical difference 
in these parameters (Table 1) (Figure 3). Tumor volume 
was significantly larger in splenectomy group (p=0.013) 
(Table 1) (Figure 4).
Tumor metastases patterns
Severe ascites was observed in 5 (33.3%) mice of 
the control group and 10 (66.7%) mice of the splenectomy 
group but without statistical  significance (p=0.068). 
Peritoneal seeding was more frequently identified in the 
splenectomy group when compared to the control group 
(11 [73.3%] vs. 4 [26.7%], respectively, p=0.011). Liver 
metastasis was observed in only one mouse of the control 
group. Kidney metastases were observed in one mouse of 
each group (Table 1).
Tumor-infiltrating T lymphocyte analysis
The ratios of CD4+ to FoxP3+ and CD8+ to FoxP3+ 
were significantly higher in control group compared to 
splenectomy group (8.2 ± 9.3 vs. 2.4 ± 1.5, p=0.046; 2.5 ± 
1.4 vs. 1.5 ± 0.4, p=0.031, respectively) (Table 2).
DISCUSSION
This study investigated the impact of splenectomy 
on tumor growth and host immunity in an orthotopic 
syngeneic pancreatic cancer mouse model. The results 
showed that the tumor volume was significantly larger and 
peritoneal seeding was more frequent in the splenectomy 
group compared to the control group. The tumor growth 
pattern in the splenectomized mice was thus associated 
with more aggressive behavior.
Although the impact of splenectomy on 
experimental models with several kinds of cancer has 
been studied, the exact mechanism of splenectomy on 
cancer growth remains uncertain. Shiratori et al [10] and 
Imai et al [9] reported that the number of hepatic and 
lung metastases increased in splenectomized mice using 
colon-cancer and liver-tumor models, respectively. They 
postulated that the mechanism of the increased liver and 
pulmonary metastases was due to decreased activity of 
Figure 1: Schema of experimental plan. Small fragments (3 mm) of murine pancreatic cancer (PAN02), previously grown 
subcutaneously, were orthotopically implanted in the pancreatic tail of C57/BL6 mice without splenectomy (A, control group) or with 
splenectomy (B, splenectomy group).
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NK cells after splenectomy [9, 10]. In these previous 
reports to demonstrate the impact of splenectomy on 
tumor growth, cancer cells were directly injected into the 
superior mesenteric vein or liver parenchyma to establish 
an experimental model of liver metastasis of colon cancer. 
When the cancer cells are injected in a vein or into the 
liver parenchyma, there is a chance of widespread cancer 
cell dissemination or intravasation into the portal vein 
or hepatic vein. With these experimental designs, cancer 
cells enter the circulation at the initial stage of tumor 
growth which is a different situation from natural tumor 
growth and metastasis. In our study, we orthotopically 
implanted tumor fragments in the pancreas tail which is 
a very similar situation to the clinical setting of patients 
with left-sided pancreatic cancer. In those cases, we can 
try to preserve the spleen in well-selected patients (for 
example, no evidence of tumor invasion to the spleen, no 
splenic hilum lymph node metastasis, small sized tumor 
etc.) during distal pancreatectomy.
Another possible mechanism for the splenectomy 
effect on aggressive tumor behavior is that regulatory 
T cells may increase in some organs. Higashijima 
et al reported that the number of hepatic metastases 
significantly increased in the splenectomy group compared 
to the spleen-preserved group after colon cancer cells were 
injected into spleen [8]. They concluded that splenectomy 
enhanced hepatic metastasis through the increase of 
Foxp3 mRNA in the liver. Future studies will focus on 
the mechanism of increased metastases after splenectomy 
during pancreatectomy.
Our results showed that the relative ratios 
of CD4+ helper T lymphocyte to FoxP3+ Treg and 
Figure 2: Procedures of surgical orthotopic implantation (SOI) of pancreatic cancer tumor fragments with 
simultaneous splenectomy. A small 6-10 mm transverse incision was made on the left flank of mice through the skin and peritoneum. 
The pancreatic tail and spleen were exposed through this incision (A, B). The splenic artery and vein in the splenic hilum (white arrows) 
and short gastric vessels communicating with the splenic upper pole (white arrow head) were securely ligated (C). After the spleen was 
removed (D), a single tumor fragment (3 mm3) was sutured to the pancreas tail using 7-0 nylon surgical sutures (white arrow head), (E). 
Upon completion, the pancreatic tail was returned to the abdomen, and the incision was closed in one layer using 6-0 nylon surgical 
sutures (F).
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CD8+ cytotoxic T lymphocytes to FoxP3+ Treg were 
significantly higher in the control group compared to 
the splenectomy group. We also previously reported 
that the ratios of helper T cells or cytotoxic T cells 
to Treg cells were significantly related to survival in 
patients with gastric and pancreatic cancer [11, 12]. 
Shang reported in their review that high FoxP3+ Treg 
infiltration was significantly associated with shorter 
overall survival in the majority of cases [13]. Future 
experiments will measure other immune cells including 
myeloid-derived suppressor cells, NK cells, M1 and M2 
macrophages as well as time-course studies of the actual 
numbers of CD4+ helper lymphocytes, FoxP3+Treg, and 
CD8+ cytotoxic T lymphocytes during pancreatic tumor 
growth and metastasis in control and splenectomized 
mice.
When we consider the clinical setting, spleen-
preserving distal pancreatectomy can be attempted at 
the time of cancer surgery in patients with PDAC. In 
addition, the impact of splenectomy on tumor recurrence 
and oncologic outcomes will be further investigated with 
orthotopic syngeneic models using other mouse pancreatic 
cancer cell lines as well as patient pancreatic cancer in 
orthotopic humanized mouse models. Future experiments 
Table 1: Tumor growth and metastatic pattern in splenectomized and control mice
Control 
group
(n=15)
Splenectomy group
(n=15)
p-value
Body weight at SOI 19.3 ± 2.6 18.18 ± 3.2 0.320
Body weight at laparotomy 21.8 ± 2.6 21.5 ± 3.4 0.797
Postoperative death 1.000
 No 15 (100%) 14 (93.3%)
 Yes 0 1 (6.7%)
Tumor rejection 1.000
 No 14 (93.3%) 15 (100%)
 Yes 1 (6.7%) 0
Tumor growth 0.169
 No 5 (33.3%) 1 (6.7%)
 Yes 10 (66.7%) 14 (93.3%)
Tumor size (length), mm 8.8 ± 5.0 11.3 ± 4.3 0.180
Tumor size (width), mm 6.2 ± 2.7 9.3 ± 3.8 0.017
Tumor volume, mm3 244.1 ± 239.5 697.9 ± 543.4 0.013
Ascites 0.068
 No 10 (66.7%) 5 (33.3%)
 Yes 5 (33.3%) 10 (66.7%)
Peritoneal seeding 0.011
 No 11 (73.3%) 4 (26.7%)
 Yes 4 (26.7%) 11 (73.3%)
Liver metastasis 1.000
 No 14 (93.3%) 15 (100%)
 Yes 1 (6.7%) 0
Kidney metastasis 1.000
 No 14 (93.3%) 14 (93.3%)
 Yes 1 (6.7%) 1 (6.7%)
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Figure 3: Tumor growth patterns at laparotomy. (A) The implanted tumor disappeared and only peritoneal fat was attached around 
surgical bed in one mouse (yellow dotted circle). (B) If the tumor grew to less than 5 mm, the tumor growth pattern was defined as ‘no 
growth’ (dotted circle) in a mouse in the control group. (C) Large pancreatic tumor (yellow dotted circle), kidney metastasis (white arrow 
head), and peritoneal seeding (black arrow head) were observed in a mouse in the splenectomy group. (D) Liver metastasis was observed 
in one mouse (white arrow head).
Figure 4: Tumor size and volume in splenectomy and control groups. Tumor width and total tumor volume were significantly 
larger in the splenectomy group compared to the control group.
Oncotarget88832www.impactjournals.com/oncotarget
will determine if there is a difference in tumor recurrence 
or survival depending on spleen preservation or not 
during tumor resection in an orthotopic pancreatic cancer 
mouse model. Reimplantation of spleen fragments after 
pancreatectomy will also be done in the mouse models 
to determine if this can restore efficient antitumor mouse 
function. Clinical studies will also be performed to 
further understand the tumor immunological effects of 
splenectomy which will be measured by flow cytometry 
as well as immunohistochemistry.
The present experiment, to our knowledge, is 
the first study to examine the effect of splenectomy 
on tumor growth and host immunity in a syngeneic 
orthotopic murine pancreatic cancer model. In conclusion, 
splenectomy enhanced tumor growth and peritoneal 
seeding. The high ratio of tumor-infiltrating helper T 
or cytotoxic T lymphocytes to Treg cells seems to have 
important anti-tumor immunity in the control group. The 
present results suggest that splenectomy be avoided during 
pancreatic resection for PDAC whenever possible.
MATERIALS AND METHODS
Cell culture
The murine pancreatic cancer cell line, PAN02, 
was maintained in Dulbecco’s Modified Eagle’s Medium 
(DMEM; Invitrogen, Melbourne, Australia) supplemented 
with 10% fetal bovine serum (FBS; Sigma-Aldrich, 
St. Louis, MO). The cells were incubated at 37oC in a 
humidified incubator of 5% CO2 in air. The cells were 
collected after trypsinization and stained with trypan blue 
(Sigma-Aldrich, St. Louis, MO). Only viable cells which 
excluded trypan blue were counted with a hemocytometer 
(Hausser Scientific, Horsham, PA).
Animals
Athymic nu/nu nude and C57/BL6 immunocompetent 
mice (AntiCancer Inc., San Diego, CA), 4–6 weeks old, were 
used for subcutaneous cancer cell injection to obtain stock 
tumor and orthotopic tumor implant models, respectively. 
Mice were kept in a barrier facility under HEPA filtration and 
fed with autoclaved laboratory rodent diet. All mouse surgical 
procedures were performed with the animals anesthetized 
by intramuscular injection of a 0.02 ml solution of 50% 
ketamine, 38% xylazine, and 12% acepromazine maleate. 
The animals were sacrificed at day 21 after surgery for 
measuring tumor growth. All animal studies were conducted 
with an AntiCancer Institutional Animal Care and Use 
Committee (IACUC)-protocol specifically approved for this 
study and in accordance with the principles and procedures 
outlined in the National Institute of Health Guide for the Care 
and Use of Animals under Assurance Number A3873-1.
Subcutaneous cancer cell injection
PAN02 cells were harvested by trypsinization 
and washed twice with phosphate buffered saline (PBS; 
Sigma Aldrich). PAN02 cells (2 x 106) were injected 
subcutaneously into the right and left flanks of nude mice 
within 30 min of harvesting. The resulting subcutaneous 
tumors were harvested for subsequent surgical orthotopic 
implantation (SOI).
Orthotopic tumor implantation and 
simultaneous splenectomy
Surgical orthotopic implantation (SOI) of tumor 
fragments was performed in C57/BL6 mice, as previously 
described [14–17]. The mice were divided into two groups 
according to splenectomy or no splenectomy. A small 6-10 
mm transverse incision was made on the left flank of the 
mouse through the skin and peritoneum. The pancreas tail 
and spleen were exposed through this incision, and a single 
tumor fragment (3 mm3), harvested from a subcutaneous 
tumor grown on a nude mouse, was sutured to the tail of 
the pancreas using 7-0 nylon surgical sutures (DermalonTM, 
Covidien; Medtronic Inc., MN, USA). In the control group, 
the pancreatic tail and spleen were returned to the abdomen, 
and the incision was closed in one layer using 6-0 nylon 
surgical sutures (DermalonTM). In the splenectomy group, 
the splenic artery and vein in the splenic hilum and short 
gastric vessels communicating with the splenic upper pole 
were securely ligated with 7-0 nylon sutures (DermalonTM). 
After the spleen was removed, a single tumor fragment was 
sutured to the pancreatic tail (Figure 2). Fifteen mice were 
used in both the control and splenectomy groups.
Tumor growth and metastatic pattern analysis
Tumor growth patterns were analyzed by 
laparotomy. The animals were sacrificed 21 days after 
surgery. Tumor length and width were measured with 
calipers and tumor volume was calculated by the following 
formula: tumor volume = (length x width2)/2. In addition, 
Table 2: Tumor infiltrating lymphocyte subset ratios in the splenectomized and control mice
Control group
(n=14)
Splenectomy group
(n=15)
p-value
CD4+/FoxP3+ 8.2 ± 9.3 2.4 ± 1.5 0.046
CD8+/FoxP3+ 2.5 ± 1.4 1.5 ± 0.4 0.031
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the peritoneal cavity was carefully assessed for the 
evidence of peritoneal, hepatic, or other site metastases.
Immunohistochemical staining and 
quantification of tumor-infiltrating T 
lymphocyte subsets
Immunohistochemical (IHC) staining for tumor-
infiltrating T lymphocyte subsets was performed 
as previously described [11, 12]. Briefly, paraffin-
embedded tumor tissue sections at a thickness of 
4-μm were deparaffinized in xylene and rehydrated in 
decreasing concentrations of ethanol. Antigen retrieval 
was performed in citrate buffer in a microwave oven. 
Endogenous peroxidase activity was blocked by 
incubating the tissue with 3% hydrogen peroxide in 
methanol for 5 min. The sections were incubated for 
60 min at room temperature with primary monoclonal 
antibodies against a cluster of differentiation antigens 
(CD4 [Cat. No. ab183685, 1:100, Abcam, Cambridge, 
UK], CD8 [Cat. No. ab203035, 1:100, Abcam], and 
Foxp3 [Cat. No. ab20034, 1:100, Abcam]), which 
were used to identify helper T lymphocytes, cytotoxic 
T lymphocytes, and regulatory T lymphocyte (Treg), 
respectively. After washing the sections twice with 
0.05 mol/l Tris-buffered saline with 0.2% Tween-20, 
the sections were incubated with horseradish 
peroxidase-conjugated secondary antibody (Dako 
EnVision®Detection system, Dako, Glostrup, Denmark), 
followed by development with diaminobenzidine and 
counterstaining with hematoxylin. IHC staining was 
quantified by an experienced pathologist (SHK) who was 
blinded to the data. Three intense foci of staining in the 
tumor sections were selected and three high-power fields 
(magnification, x400) from each slide were selected for 
calculation of IHC staining result.
Statistical analysis
All statistical analyses were performed with SPSS 
20.0 software (IBM, New York, NY, USA). Categorical 
variables were compared using χ2 or Fisher exact tests. 
Continuous variables are presented as mean ± standard 
deviation (SD) and the significance was determined using 
Student’s t-test. Bar graph expressed mean value, and 
error bars show -SD. A p-value of 0.05 or less indicated 
statistical significance.
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